Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | Monoclonal antibody therapies for multiple myeloma

Mattia D'Agostino • 26 Feb 2021
EMN 2021
Multiple Myeloma Antibodies Daratumumab

Mattia D’Agostino, MD, University of Torino, Turin, Italy, discusses the latest developments in the field of monoclonal antibodies for the treatment of multiple myeloma, highlighting the approval of daratumumab in the front-line for newly diagnosed patients. Dr D’Agostino says he believes monoclonal antibodies will likely be incorporated in every line of therapy for multiple myeloma in the future, due to their promising safety and efficacy results. Dr D’Agostino also says he anticipates improvements in patient outcomes with anti-CD38 monoclonal antibody therapy. This interview took place during the 2021 European Myeloma Network (EMN) congress.

More from Mattia D'Agostino

1:07
The second revision of the International Staging System for OS in MM
Mattia D'Agostino • 28 Sep 2023
1:28
EMN20: KRd versus Rd in non-frail, transplant-ineligible patients with NDMM
Mattia D'Agostino • 28 Sep 2023
1:25
Immune reconstitution and vaccination in multiple myeloma
Mattia D'Agostino • 25 Aug 2022
1:38
Using MRD to guide therapy in multiple myeloma
Mattia D'Agostino • 26 Aug 2022

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals